| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 41 | 2026 | 1163 | 3.860 |
Why?
|
| Microbiota | 26 | 2026 | 730 | 2.760 |
Why?
|
| Infant, Premature | 15 | 2026 | 620 | 2.680 |
Why?
|
| Bronchopulmonary Dysplasia | 13 | 2026 | 420 | 2.590 |
Why?
|
| Pseudomonas Infections | 6 | 2023 | 231 | 1.900 |
Why?
|
| Retinopathy of Prematurity | 11 | 2024 | 181 | 1.700 |
Why?
|
| Macular Degeneration | 8 | 2023 | 191 | 1.600 |
Why?
|
| Bacteria | 19 | 2026 | 766 | 1.480 |
Why?
|
| Gestational Age | 21 | 2026 | 990 | 1.430 |
Why?
|
| Bronchoalveolar Lavage Fluid | 12 | 2026 | 638 | 1.180 |
Why?
|
| Trachea | 5 | 2026 | 258 | 1.160 |
Why?
|
| Hypertension, Pulmonary | 11 | 2023 | 1957 | 1.090 |
Why?
|
| Lung | 23 | 2026 | 4116 | 1.080 |
Why?
|
| RNA, Ribosomal, 16S | 17 | 2026 | 508 | 1.070 |
Why?
|
| Respiratory Tract Infections | 9 | 2026 | 396 | 1.070 |
Why?
|
| Birth Weight | 8 | 2024 | 517 | 1.020 |
Why?
|
| Sputum | 14 | 2026 | 302 | 1.000 |
Why?
|
| Retinal Drusen | 3 | 2021 | 31 | 0.980 |
Why?
|
| Geographic Atrophy | 6 | 2025 | 97 | 0.950 |
Why?
|
| Gastrointestinal Microbiome | 10 | 2026 | 768 | 0.940 |
Why?
|
| Infant, Newborn | 33 | 2026 | 6465 | 0.840 |
Why?
|
| Humans | 167 | 2026 | 145783 | 0.800 |
Why?
|
| Anti-Bacterial Agents | 13 | 2024 | 1925 | 0.790 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 69 | 0.770 |
Why?
|
| Female | 119 | 2026 | 79045 | 0.750 |
Why?
|
| Premature Birth | 5 | 2017 | 390 | 0.750 |
Why?
|
| Male | 108 | 2026 | 73011 | 0.700 |
Why?
|
| Weight Gain | 5 | 2019 | 561 | 0.690 |
Why?
|
| Inflammation | 17 | 2026 | 2884 | 0.680 |
Why?
|
| Echocardiography, Doppler | 3 | 2018 | 115 | 0.660 |
Why?
|
| Child | 60 | 2026 | 22740 | 0.650 |
Why?
|
| Models, Statistical | 5 | 2016 | 672 | 0.640 |
Why?
|
| Proteomics | 11 | 2024 | 1188 | 0.640 |
Why?
|
| Respiratory System | 5 | 2026 | 150 | 0.630 |
Why?
|
| Down Syndrome | 2 | 2025 | 525 | 0.610 |
Why?
|
| Heart Diseases | 1 | 2023 | 341 | 0.610 |
Why?
|
| Diabetic Retinopathy | 4 | 2023 | 210 | 0.590 |
Why?
|
| Schizophrenia | 7 | 2017 | 464 | 0.590 |
Why?
|
| Respiratory Function Tests | 12 | 2026 | 544 | 0.550 |
Why?
|
| Phacoemulsification | 4 | 2023 | 123 | 0.530 |
Why?
|
| Biomarkers | 22 | 2026 | 4302 | 0.520 |
Why?
|
| Intubation, Intratracheal | 2 | 2017 | 327 | 0.520 |
Why?
|
| Infant | 31 | 2026 | 10091 | 0.500 |
Why?
|
| Prospective Studies | 26 | 2026 | 8078 | 0.490 |
Why?
|
| Wet Macular Degeneration | 3 | 2025 | 58 | 0.490 |
Why?
|
| Aminophenols | 3 | 2026 | 203 | 0.470 |
Why?
|
| Vascular Diseases | 2 | 2020 | 252 | 0.470 |
Why?
|
| Risk Assessment | 6 | 2019 | 3752 | 0.470 |
Why?
|
| Cataract | 5 | 2023 | 238 | 0.470 |
Why?
|
| Infant, Very Low Birth Weight | 5 | 2019 | 75 | 0.460 |
Why?
|
| Risk Factors | 22 | 2025 | 10919 | 0.460 |
Why?
|
| Complement Activation | 4 | 2025 | 399 | 0.460 |
Why?
|
| Statistical Distributions | 1 | 2015 | 7 | 0.450 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2015 | 39 | 0.450 |
Why?
|
| Blood Proteins | 2 | 2015 | 239 | 0.450 |
Why?
|
| Intestines | 3 | 2014 | 354 | 0.450 |
Why?
|
| Neonatal Screening | 4 | 2018 | 179 | 0.440 |
Why?
|
| Islets of Langerhans | 4 | 2015 | 847 | 0.430 |
Why?
|
| Complement Factor B | 3 | 2022 | 106 | 0.420 |
Why?
|
| Pregnancy | 15 | 2024 | 7216 | 0.410 |
Why?
|
| Visual Acuity | 6 | 2025 | 490 | 0.410 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 750 | 0.400 |
Why?
|
| Case-Control Studies | 18 | 2025 | 3634 | 0.400 |
Why?
|
| Cohort Studies | 18 | 2024 | 6033 | 0.390 |
Why?
|
| Oropharynx | 4 | 2026 | 46 | 0.390 |
Why?
|
| Adolescent | 42 | 2026 | 22577 | 0.390 |
Why?
|
| Pseudomonas aeruginosa | 6 | 2023 | 397 | 0.380 |
Why?
|
| Pre-Eclampsia | 3 | 2024 | 206 | 0.380 |
Why?
|
| Coronary Artery Bypass | 3 | 2020 | 268 | 0.370 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2025 | 58 | 0.370 |
Why?
|
| Azithromycin | 3 | 2023 | 101 | 0.360 |
Why?
|
| Retrospective Studies | 32 | 2025 | 17330 | 0.360 |
Why?
|
| Quinolones | 3 | 2026 | 204 | 0.360 |
Why?
|
| Disease Progression | 11 | 2025 | 2865 | 0.360 |
Why?
|
| Sequence Analysis | 1 | 2011 | 34 | 0.340 |
Why?
|
| Eczema | 1 | 2012 | 66 | 0.340 |
Why?
|
| Pneumonia | 4 | 2025 | 636 | 0.340 |
Why?
|
| Algorithms | 5 | 2018 | 1851 | 0.330 |
Why?
|
| Stroke | 1 | 2020 | 1271 | 0.330 |
Why?
|
| Respiratory System Agents | 2 | 2022 | 22 | 0.330 |
Why?
|
| Child, Preschool | 25 | 2026 | 11868 | 0.330 |
Why?
|
| Hemodynamics | 4 | 2013 | 1118 | 0.320 |
Why?
|
| Pyridines | 3 | 2026 | 609 | 0.310 |
Why?
|
| Metabolomics | 4 | 2025 | 733 | 0.300 |
Why?
|
| Follow-Up Studies | 13 | 2026 | 5428 | 0.300 |
Why?
|
| Pneumonia, Bacterial | 2 | 2025 | 113 | 0.300 |
Why?
|
| Intraocular Pressure | 4 | 2018 | 330 | 0.290 |
Why?
|
| Body Mass Index | 6 | 2019 | 2447 | 0.290 |
Why?
|
| Lung Diseases, Interstitial | 4 | 2019 | 664 | 0.290 |
Why?
|
| Bronchiectasis | 2 | 2023 | 115 | 0.280 |
Why?
|
| Hypersensitivity | 1 | 2012 | 254 | 0.280 |
Why?
|
| Adult | 37 | 2026 | 40881 | 0.280 |
Why?
|
| Young Adult | 24 | 2026 | 14254 | 0.280 |
Why?
|
| Cytokines | 8 | 2026 | 2069 | 0.280 |
Why?
|
| Staphylococcus | 3 | 2017 | 74 | 0.280 |
Why?
|
| Critical Illness | 6 | 2025 | 900 | 0.280 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 478 | 0.270 |
Why?
|
| Infant, Extremely Premature | 2 | 2020 | 68 | 0.270 |
Why?
|
| Respiratory Tract Diseases | 2 | 2020 | 175 | 0.270 |
Why?
|
| Creatinine | 1 | 2010 | 515 | 0.270 |
Why?
|
| Logistic Models | 7 | 2024 | 2139 | 0.270 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2023 | 1180 | 0.260 |
Why?
|
| Neuroendocrine Cells | 4 | 2019 | 33 | 0.260 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 91 | 0.260 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 368 | 0.260 |
Why?
|
| DNA, Bacterial | 6 | 2021 | 320 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2015 | 3937 | 0.250 |
Why?
|
| Carrier State | 2 | 2026 | 78 | 0.250 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2018 | 80 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 751 | 0.250 |
Why?
|
| Cathepsin B | 1 | 2026 | 17 | 0.240 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2026 | 12 | 0.240 |
Why?
|
| Mycobiome | 1 | 2026 | 8 | 0.240 |
Why?
|
| Capsule Endoscopy | 1 | 2026 | 25 | 0.240 |
Why?
|
| Mental Disorders | 1 | 2015 | 1171 | 0.230 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2023 | 339 | 0.230 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 1103 | 0.230 |
Why?
|
| Bacterial Infections | 2 | 2020 | 247 | 0.230 |
Why?
|
| ROC Curve | 4 | 2025 | 618 | 0.230 |
Why?
|
| Chemokine CCL5 | 2 | 2023 | 40 | 0.220 |
Why?
|
| Ocular Motility Disorders | 1 | 2026 | 42 | 0.220 |
Why?
|
| Rheumatoid Factor | 3 | 2023 | 178 | 0.220 |
Why?
|
| Linear Models | 3 | 2018 | 849 | 0.220 |
Why?
|
| Choline | 2 | 2019 | 138 | 0.220 |
Why?
|
| Aged | 19 | 2025 | 26217 | 0.220 |
Why?
|
| Severity of Illness Index | 8 | 2024 | 2933 | 0.220 |
Why?
|
| Obesity | 4 | 2019 | 3118 | 0.220 |
Why?
|
| Fungi | 1 | 2026 | 121 | 0.220 |
Why?
|
| Glaucoma | 2 | 2018 | 251 | 0.220 |
Why?
|
| Keratoconus | 1 | 2025 | 23 | 0.220 |
Why?
|
| Pyrrolidines | 1 | 2026 | 125 | 0.220 |
Why?
|
| Tobramycin | 2 | 2023 | 63 | 0.210 |
Why?
|
| Bacteriological Techniques | 1 | 2025 | 66 | 0.210 |
Why?
|
| Hyperplasia | 4 | 2019 | 177 | 0.210 |
Why?
|
| Sensory Gating | 2 | 2016 | 44 | 0.210 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2025 | 56 | 0.210 |
Why?
|
| Software | 3 | 2021 | 680 | 0.210 |
Why?
|
| Cognition Disorders | 3 | 2026 | 544 | 0.210 |
Why?
|
| Pseudomonas | 2 | 2022 | 30 | 0.210 |
Why?
|
| Diseases in Twins | 1 | 2024 | 116 | 0.200 |
Why?
|
| Leukocyte Elastase | 5 | 2026 | 75 | 0.200 |
Why?
|
| Postoperative Complications | 5 | 2023 | 2977 | 0.200 |
Why?
|
| Benzodioxoles | 1 | 2026 | 161 | 0.200 |
Why?
|
| Lung Diseases | 2 | 2023 | 782 | 0.200 |
Why?
|
| Cornea | 1 | 2025 | 154 | 0.200 |
Why?
|
| Twins | 1 | 2024 | 152 | 0.200 |
Why?
|
| Colorado | 12 | 2024 | 4556 | 0.200 |
Why?
|
| Macula Lutea | 1 | 2023 | 21 | 0.200 |
Why?
|
| Benzylidene Compounds | 2 | 2017 | 20 | 0.200 |
Why?
|
| Gene Expression Profiling | 2 | 2026 | 1777 | 0.200 |
Why?
|
| Societies | 1 | 2023 | 40 | 0.200 |
Why?
|
| Survival Rate | 3 | 2020 | 2094 | 0.190 |
Why?
|
| Vitreous Body | 2 | 2022 | 117 | 0.190 |
Why?
|
| Gastrointestinal Tract | 2 | 2019 | 204 | 0.190 |
Why?
|
| Intestinal Mucosa | 3 | 2015 | 675 | 0.190 |
Why?
|
| Community-Acquired Infections | 1 | 2025 | 177 | 0.190 |
Why?
|
| Methylprednisolone | 1 | 2023 | 59 | 0.190 |
Why?
|
| Optic Neuritis | 1 | 2023 | 44 | 0.190 |
Why?
|
| Tomography | 2 | 2025 | 45 | 0.190 |
Why?
|
| Ciliary Motility Disorders | 1 | 2023 | 24 | 0.190 |
Why?
|
| Retinal Detachment | 1 | 2023 | 73 | 0.190 |
Why?
|
| Proteome | 2 | 2024 | 513 | 0.180 |
Why?
|
| Treatment Outcome | 12 | 2026 | 11794 | 0.180 |
Why?
|
| Staphylococcus aureus | 4 | 2026 | 454 | 0.180 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 2968 | 0.180 |
Why?
|
| Virus Diseases | 1 | 2024 | 216 | 0.180 |
Why?
|
| Administration, Inhalation | 1 | 2023 | 571 | 0.180 |
Why?
|
| Hippocampus | 1 | 2008 | 973 | 0.180 |
Why?
|
| Congresses as Topic | 1 | 2023 | 224 | 0.180 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.180 |
Why?
|
| Respiration, Artificial | 4 | 2023 | 714 | 0.180 |
Why?
|
| Middle Aged | 24 | 2026 | 36309 | 0.180 |
Why?
|
| Indoles | 1 | 2026 | 507 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2026 | 517 | 0.170 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 2 | 2020 | 127 | 0.170 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2012 | 109 | 0.170 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 1101 | 0.170 |
Why?
|
| Smoking | 3 | 2018 | 1477 | 0.170 |
Why?
|
| Posterior Capsulotomy | 1 | 2021 | 8 | 0.170 |
Why?
|
| Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.170 |
Why?
|
| Mothers | 5 | 2019 | 766 | 0.170 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2021 | 13 | 0.170 |
Why?
|
| Capsule Opacification | 1 | 2021 | 22 | 0.170 |
Why?
|
| Lasers, Solid-State | 1 | 2021 | 22 | 0.170 |
Why?
|
| Ethambutol | 1 | 2021 | 27 | 0.170 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2012 | 199 | 0.170 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 3 | 2017 | 94 | 0.170 |
Why?
|
| Desmosine | 2 | 2012 | 5 | 0.170 |
Why?
|
| General Surgery | 1 | 2024 | 206 | 0.160 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2022 | 81 | 0.160 |
Why?
|
| Rifampin | 1 | 2021 | 79 | 0.160 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 8347 | 0.160 |
Why?
|
| Malondialdehyde | 1 | 2020 | 31 | 0.160 |
Why?
|
| Area Under Curve | 2 | 2019 | 332 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 337 | 0.160 |
Why?
|
| Acetaldehyde | 1 | 2020 | 17 | 0.160 |
Why?
|
| Complement System Proteins | 2 | 2022 | 314 | 0.160 |
Why?
|
| Fluorescein Angiography | 4 | 2023 | 189 | 0.160 |
Why?
|
| Rhodospirillaceae | 1 | 2020 | 4 | 0.160 |
Why?
|
| Trabeculectomy | 2 | 2018 | 75 | 0.160 |
Why?
|
| Dysbiosis | 2 | 2021 | 188 | 0.160 |
Why?
|
| Glycation End Products, Advanced | 1 | 2021 | 81 | 0.160 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2023 | 227 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2019 | 2399 | 0.160 |
Why?
|
| Intensive Care Units | 2 | 2024 | 924 | 0.160 |
Why?
|
| Neural Inhibition | 2 | 2013 | 178 | 0.160 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2021 | 63 | 0.160 |
Why?
|
| Metagenomics | 3 | 2023 | 150 | 0.160 |
Why?
|
| Metagenome | 4 | 2013 | 126 | 0.150 |
Why?
|
| Angiogenic Proteins | 1 | 2020 | 15 | 0.150 |
Why?
|
| Nontuberculous Mycobacteria | 2 | 2023 | 189 | 0.150 |
Why?
|
| Cross-Sectional Studies | 9 | 2026 | 5925 | 0.150 |
Why?
|
| Retinal Neovascularization | 1 | 2019 | 29 | 0.150 |
Why?
|
| Growth Charts | 1 | 2019 | 20 | 0.150 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2018 | 53 | 0.150 |
Why?
|
| Infant, Low Birth Weight | 2 | 2017 | 156 | 0.150 |
Why?
|
| Laser Therapy | 1 | 2021 | 144 | 0.150 |
Why?
|
| Heart | 1 | 2023 | 626 | 0.150 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 5 | 2015 | 778 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1038 | 0.150 |
Why?
|
| Complement C3a | 1 | 2019 | 40 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2022 | 317 | 0.150 |
Why?
|
| Cognition | 2 | 2026 | 1271 | 0.140 |
Why?
|
| Dementia | 1 | 2023 | 328 | 0.140 |
Why?
|
| Anthropometry | 1 | 2019 | 206 | 0.140 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 45 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2019 | 143 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2026 | 534 | 0.140 |
Why?
|
| Pilocarpine | 1 | 2018 | 16 | 0.140 |
Why?
|
| Choroidal Neovascularization | 1 | 2019 | 56 | 0.140 |
Why?
|
| Medical History Taking | 1 | 2019 | 117 | 0.140 |
Why?
|
| Nocturnal Myoclonus Syndrome | 1 | 2018 | 6 | 0.140 |
Why?
|
| Autoantibodies | 3 | 2023 | 1509 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 288 | 0.140 |
Why?
|
| Bayes Theorem | 2 | 2018 | 421 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 118 | 0.140 |
Why?
|
| Ophthalmic Solutions | 1 | 2018 | 82 | 0.130 |
Why?
|
| Feces | 3 | 2018 | 496 | 0.130 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2018 | 23 | 0.130 |
Why?
|
| Aptamers, Nucleotide | 1 | 2019 | 87 | 0.130 |
Why?
|
| C-Reactive Protein | 5 | 2021 | 423 | 0.130 |
Why?
|
| Research Design | 3 | 2019 | 1139 | 0.130 |
Why?
|
| Brain Concussion | 1 | 2026 | 646 | 0.130 |
Why?
|
| Liver | 2 | 2018 | 1899 | 0.130 |
Why?
|
| Trabecular Meshwork | 1 | 2018 | 74 | 0.130 |
Why?
|
| Respiration Disorders | 1 | 2018 | 78 | 0.130 |
Why?
|
| Specimen Handling | 2 | 2020 | 183 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2019 | 136 | 0.130 |
Why?
|
| Metformin | 1 | 2021 | 329 | 0.130 |
Why?
|
| Ocular Hypertension | 1 | 2018 | 70 | 0.130 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 199 | 0.130 |
Why?
|
| Histones | 1 | 2023 | 666 | 0.130 |
Why?
|
| Age Factors | 4 | 2018 | 3346 | 0.130 |
Why?
|
| Clofazimine | 1 | 2017 | 15 | 0.130 |
Why?
|
| Chorioamnionitis | 1 | 2017 | 50 | 0.130 |
Why?
|
| Maternal Exposure | 1 | 2019 | 189 | 0.130 |
Why?
|
| Pulmonary Artery | 3 | 2013 | 1129 | 0.130 |
Why?
|
| Registries | 3 | 2024 | 2410 | 0.130 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.120 |
Why?
|
| Labor, Induced | 1 | 2017 | 40 | 0.120 |
Why?
|
| Labor, Obstetric | 1 | 2017 | 68 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 1330 | 0.120 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2018 | 104 | 0.120 |
Why?
|
| Hypoxia | 2 | 2018 | 1199 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 3 | 2025 | 270 | 0.120 |
Why?
|
| Fusobacterium | 1 | 2016 | 2 | 0.120 |
Why?
|
| Fusobacterium Infections | 1 | 2016 | 7 | 0.120 |
Why?
|
| Haemophilus | 1 | 2016 | 8 | 0.120 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2017 | 107 | 0.120 |
Why?
|
| Diastole | 2 | 2013 | 146 | 0.120 |
Why?
|
| Social Class | 1 | 2018 | 264 | 0.120 |
Why?
|
| Ventricular Function, Right | 1 | 2018 | 297 | 0.120 |
Why?
|
| Sensitivity and Specificity | 5 | 2025 | 2000 | 0.120 |
Why?
|
| Haemophilus Infections | 1 | 2016 | 46 | 0.110 |
Why?
|
| Esophagitis | 1 | 2016 | 67 | 0.110 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2018 | 248 | 0.110 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 211 | 0.110 |
Why?
|
| Cataract Extraction | 1 | 2016 | 120 | 0.110 |
Why?
|
| Nose | 1 | 2015 | 67 | 0.110 |
Why?
|
| Leukocyte L1 Antigen Complex | 3 | 2022 | 41 | 0.110 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 139 | 0.110 |
Why?
|
| Pulmonary Fibrosis | 1 | 2019 | 395 | 0.110 |
Why?
|
| Attention | 3 | 2016 | 463 | 0.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 265 | 0.110 |
Why?
|
| Bronchi | 1 | 2016 | 263 | 0.110 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2016 | 430 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2012 | 50 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 2181 | 0.110 |
Why?
|
| Phenotype | 5 | 2025 | 3170 | 0.110 |
Why?
|
| Phylogeny | 1 | 2018 | 917 | 0.110 |
Why?
|
| Time Factors | 6 | 2025 | 7134 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 440 | 0.100 |
Why?
|
| Pediatric Obesity | 2 | 2019 | 638 | 0.100 |
Why?
|
| Mutation | 3 | 2022 | 4090 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2019 | 655 | 0.100 |
Why?
|
| RNA, Bacterial | 1 | 2015 | 182 | 0.100 |
Why?
|
| Staphylococcal Infections | 2 | 2015 | 393 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 314 | 0.100 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2013 | 30 | 0.100 |
Why?
|
| Paranasal Sinuses | 1 | 2014 | 81 | 0.100 |
Why?
|
| Hydrocortisone | 1 | 2016 | 298 | 0.100 |
Why?
|
| Brain | 2 | 2019 | 2969 | 0.100 |
Why?
|
| Evoked Potentials, Auditory | 2 | 2016 | 181 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2012 | 376 | 0.100 |
Why?
|
| Parenteral Nutrition | 1 | 2014 | 102 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 92 | 0.100 |
Why?
|
| Forced Expiratory Volume | 3 | 2020 | 450 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 1547 | 0.100 |
Why?
|
| Veterans | 1 | 2026 | 1642 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1327 | 0.100 |
Why?
|
| Database Management Systems | 1 | 2013 | 51 | 0.100 |
Why?
|
| Computer Graphics | 1 | 2013 | 41 | 0.100 |
Why?
|
| Asthma | 2 | 2019 | 1797 | 0.100 |
Why?
|
| Phosphorylcholine | 1 | 2013 | 19 | 0.100 |
Why?
|
| Machine Learning | 1 | 2019 | 587 | 0.100 |
Why?
|
| Affect | 1 | 2016 | 321 | 0.100 |
Why?
|
| Saliva | 1 | 2015 | 249 | 0.090 |
Why?
|
| Nootropic Agents | 1 | 2013 | 30 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2024 | 1269 | 0.090 |
Why?
|
| Data Mining | 1 | 2014 | 113 | 0.090 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 119 | 0.090 |
Why?
|
| Parvovirus | 1 | 2012 | 13 | 0.090 |
Why?
|
| Receptors, Nicotinic | 3 | 2013 | 327 | 0.090 |
Why?
|
| Fetus | 2 | 2018 | 804 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2016 | 443 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2015 | 237 | 0.090 |
Why?
|
| Nasopharynx | 2 | 2023 | 72 | 0.090 |
Why?
|
| Propanolamines | 1 | 2012 | 40 | 0.090 |
Why?
|
| Rhinitis | 1 | 2014 | 169 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2016 | 583 | 0.090 |
Why?
|
| Bronchiolitis | 1 | 2013 | 87 | 0.090 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2012 | 14 | 0.090 |
Why?
|
| User-Computer Interface | 1 | 2013 | 165 | 0.090 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 3 | 2022 | 373 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1166 | 0.090 |
Why?
|
| Nicotinic Agonists | 2 | 2017 | 135 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 251 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 1043 | 0.090 |
Why?
|
| Body Fluids | 1 | 2012 | 71 | 0.090 |
Why?
|
| Bacterial Translocation | 1 | 2012 | 52 | 0.090 |
Why?
|
| Sinusitis | 1 | 2014 | 227 | 0.090 |
Why?
|
| Elastin | 1 | 2012 | 78 | 0.090 |
Why?
|
| Reference Values | 2 | 2010 | 798 | 0.090 |
Why?
|
| Placenta | 1 | 2018 | 787 | 0.080 |
Why?
|
| HLA-DQ Antigens | 1 | 2012 | 174 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 252 | 0.080 |
Why?
|
| United States | 8 | 2024 | 16126 | 0.080 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 220 | 0.080 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 514 | 0.080 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2015 | 332 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 90 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2020 | 867 | 0.080 |
Why?
|
| Immunoglobulin M | 2 | 2023 | 265 | 0.080 |
Why?
|
| Specific Gravity | 1 | 2010 | 13 | 0.080 |
Why?
|
| Esophagus | 1 | 2012 | 262 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2019 | 1083 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 371 | 0.080 |
Why?
|
| Quality of Life | 2 | 2023 | 3211 | 0.080 |
Why?
|
| Aorta | 1 | 2013 | 441 | 0.080 |
Why?
|
| Gene Library | 1 | 2010 | 122 | 0.080 |
Why?
|
| Chloride Channel Agonists | 2 | 2026 | 110 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2010 | 153 | 0.080 |
Why?
|
| Autoimmunity | 2 | 2015 | 933 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2021 | 1001 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2026 | 396 | 0.070 |
Why?
|
| Epoprostenol | 1 | 2009 | 132 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2013 | 756 | 0.070 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2009 | 92 | 0.070 |
Why?
|
| Lung Injury | 1 | 2012 | 249 | 0.070 |
Why?
|
| Genotype | 4 | 2018 | 1857 | 0.070 |
Why?
|
| Memory, Short-Term | 2 | 2008 | 269 | 0.070 |
Why?
|
| Tonometry, Ocular | 2 | 2018 | 104 | 0.070 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2025 | 293 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2026 | 1812 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2012 | 697 | 0.070 |
Why?
|
| Schizophrenia, Childhood | 1 | 2007 | 3 | 0.070 |
Why?
|
| Models, Biological | 3 | 2026 | 1764 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 2009 | 123 | 0.070 |
Why?
|
| Linguistics | 1 | 2007 | 26 | 0.060 |
Why?
|
| Child of Impaired Parents | 1 | 2007 | 38 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2016 | 1151 | 0.060 |
Why?
|
| Neuropsychological Tests | 3 | 2026 | 1137 | 0.060 |
Why?
|
| Pulmonary Circulation | 1 | 2009 | 430 | 0.060 |
Why?
|
| Bacteremia | 1 | 2009 | 222 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2601 | 0.060 |
Why?
|
| Culture | 1 | 2007 | 124 | 0.060 |
Why?
|
| Thoracic Surgery | 1 | 2008 | 143 | 0.060 |
Why?
|
| Transcriptome | 2 | 2026 | 1042 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2007 | 197 | 0.060 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2006 | 16 | 0.060 |
Why?
|
| Review Literature as Topic | 1 | 2026 | 52 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2026 | 84 | 0.060 |
Why?
|
| Health Surveys | 1 | 2008 | 520 | 0.060 |
Why?
|
| Inpatients | 1 | 2010 | 553 | 0.060 |
Why?
|
| Corneal Topography | 1 | 2025 | 25 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 521 | 0.060 |
Why?
|
| Vital Capacity | 1 | 2026 | 292 | 0.050 |
Why?
|
| Hospitals, Veterans | 1 | 2006 | 258 | 0.050 |
Why?
|
| Quinolines | 1 | 2026 | 190 | 0.050 |
Why?
|
| Bed Occupancy | 1 | 2024 | 16 | 0.050 |
Why?
|
| Respiratory Sounds | 1 | 2025 | 103 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 2770 | 0.050 |
Why?
|
| Echocardiography | 3 | 2013 | 648 | 0.050 |
Why?
|
| Equipment Design | 2 | 2018 | 525 | 0.050 |
Why?
|
| Vision Tests | 1 | 2023 | 22 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2024 | 64 | 0.050 |
Why?
|
| Specialty Boards | 1 | 2024 | 42 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 5993 | 0.050 |
Why?
|
| Hospitalization | 2 | 2015 | 2461 | 0.050 |
Why?
|
| Biofilms | 1 | 2026 | 292 | 0.050 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2023 | 25 | 0.050 |
Why?
|
| Spirometry | 2 | 2015 | 233 | 0.050 |
Why?
|
| Systole | 2 | 2013 | 181 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2024 | 227 | 0.050 |
Why?
|
| Neuroprotection | 1 | 2023 | 46 | 0.050 |
Why?
|
| Dyneins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Vimentin | 1 | 2023 | 54 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2025 | 627 | 0.050 |
Why?
|
| Cotinine | 1 | 2023 | 77 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2023 | 147 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2023 | 207 | 0.050 |
Why?
|
| Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
|
| Viral Load | 1 | 2024 | 526 | 0.050 |
Why?
|
| Calreticulin | 1 | 2022 | 22 | 0.050 |
Why?
|
| Neutrophils | 2 | 2021 | 1127 | 0.050 |
Why?
|
| HMGB Proteins | 1 | 2022 | 15 | 0.040 |
Why?
|
| Aqueous Humor | 1 | 2022 | 40 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2023 | 147 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2023 | 105 | 0.040 |
Why?
|
| Aspergillus fumigatus | 1 | 2021 | 26 | 0.040 |
Why?
|
| Ecosystem | 1 | 2026 | 478 | 0.040 |
Why?
|
| Capsulorhexis | 1 | 2021 | 9 | 0.040 |
Why?
|
| Haemophilus influenzae | 1 | 2022 | 68 | 0.040 |
Why?
|
| Albumins | 1 | 2022 | 119 | 0.040 |
Why?
|
| Smoke | 1 | 2023 | 148 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 214 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2021 | 67 | 0.040 |
Why?
|
| Familial Primary Pulmonary Hypertension | 2 | 2012 | 196 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2023 | 979 | 0.040 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2021 | 35 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1512 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2022 | 167 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2022 | 180 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2023 | 442 | 0.040 |
Why?
|
| Choroid | 1 | 2021 | 80 | 0.040 |
Why?
|
| Lenses, Intraocular | 1 | 2021 | 49 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2024 | 326 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 37 | 0.040 |
Why?
|
| Animals | 8 | 2019 | 38102 | 0.040 |
Why?
|
| Mycobacterium avium Complex | 1 | 2021 | 87 | 0.040 |
Why?
|
| Leptin | 1 | 2022 | 248 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 3418 | 0.040 |
Why?
|
| Systems Biology | 1 | 2021 | 68 | 0.040 |
Why?
|
| Mice | 5 | 2019 | 18356 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2017 | 2064 | 0.040 |
Why?
|
| Vitrectomy | 1 | 2020 | 73 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2019 | 32 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1998 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 971 | 0.040 |
Why?
|
| Sweat | 1 | 2020 | 51 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 260 | 0.040 |
Why?
|
| Western World | 1 | 2019 | 7 | 0.040 |
Why?
|
| Interleukin-8 | 2 | 2012 | 269 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 48 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 99 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 450 | 0.040 |
Why?
|
| Workflow | 1 | 2021 | 183 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2019 | 3130 | 0.040 |
Why?
|
| Respiratory Rate | 1 | 2019 | 24 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2021 | 208 | 0.040 |
Why?
|
| Exercise Test | 2 | 2012 | 630 | 0.040 |
Why?
|
| Heart Failure | 1 | 2012 | 2326 | 0.040 |
Why?
|
| Cardiac Catheterization | 2 | 2013 | 559 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 365 | 0.040 |
Why?
|
| Norway | 1 | 2018 | 41 | 0.040 |
Why?
|
| Maternal Age | 1 | 2019 | 128 | 0.040 |
Why?
|
| Coinfection | 1 | 2020 | 143 | 0.040 |
Why?
|
| Rats | 3 | 2012 | 5585 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 610 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 562 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 892 | 0.030 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.030 |
Why?
|
| Axial Length, Eye | 1 | 2018 | 16 | 0.030 |
Why?
|
| Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
|
| Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
|
| Pseudophakia | 1 | 2018 | 21 | 0.030 |
Why?
|
| Oximetry | 1 | 2019 | 125 | 0.030 |
Why?
|
| Electroencephalography | 2 | 2013 | 563 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 572 | 0.030 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2019 | 121 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2025 | 995 | 0.030 |
Why?
|
| Prognosis | 3 | 2012 | 4330 | 0.030 |
Why?
|
| Refraction, Ocular | 1 | 2018 | 47 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 6085 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 1217 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2018 | 108 | 0.030 |
Why?
|
| Bifidobacterium | 1 | 2017 | 21 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2018 | 138 | 0.030 |
Why?
|
| Genes, rRNA | 1 | 2017 | 38 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 2123 | 0.030 |
Why?
|
| Biopsy | 2 | 2012 | 1082 | 0.030 |
Why?
|
| Gene Expression | 1 | 2022 | 1478 | 0.030 |
Why?
|
| Incidence | 2 | 2018 | 2934 | 0.030 |
Why?
|
| Archaeal Proteins | 1 | 2017 | 50 | 0.030 |
Why?
|
| North America | 1 | 2018 | 304 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 849 | 0.030 |
Why?
|
| Schizophrenic Psychology | 1 | 2017 | 99 | 0.030 |
Why?
|
| Lipids | 1 | 2022 | 707 | 0.030 |
Why?
|
| Parity | 1 | 2017 | 111 | 0.030 |
Why?
|
| Causality | 1 | 2017 | 127 | 0.030 |
Why?
|
| Polysomnography | 1 | 2018 | 239 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2019 | 264 | 0.030 |
Why?
|
| Curriculum | 1 | 2024 | 1074 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 189 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 210 | 0.030 |
Why?
|
| Laser Coagulation | 1 | 2017 | 80 | 0.030 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2016 | 24 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2022 | 789 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4568 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 20 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 1752 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 172 | 0.030 |
Why?
|
| Fetal Development | 1 | 2019 | 298 | 0.030 |
Why?
|
| Antibiosis | 1 | 2015 | 10 | 0.030 |
Why?
|
| Streptococcus mitis | 1 | 2015 | 10 | 0.030 |
Why?
|
| Lactobacillus | 1 | 2015 | 28 | 0.030 |
Why?
|
| Family | 2 | 2012 | 685 | 0.030 |
Why?
|
| Hair | 1 | 2016 | 84 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 923 | 0.030 |
Why?
|
| Catalase | 1 | 2015 | 134 | 0.030 |
Why?
|
| Capsule Endoscopes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Child Behavior Disorders | 1 | 2016 | 119 | 0.030 |
Why?
|
| Radiography | 1 | 2017 | 853 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2016 | 155 | 0.030 |
Why?
|
| Probability | 1 | 2016 | 308 | 0.030 |
Why?
|
| Problem Behavior | 1 | 2016 | 101 | 0.030 |
Why?
|
| Heart Rate | 1 | 2019 | 856 | 0.030 |
Why?
|
| Cell Line | 2 | 2012 | 2823 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2015 | 65 | 0.030 |
Why?
|
| Enterobacteriaceae | 1 | 2015 | 44 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2014 | 21 | 0.030 |
Why?
|
| Plant Oils | 1 | 2014 | 33 | 0.030 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2015 | 42 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 89 | 0.030 |
Why?
|
| Kupffer Cells | 1 | 2014 | 52 | 0.030 |
Why?
|
| Permeability | 1 | 2015 | 169 | 0.030 |
Why?
|
| Proteins | 1 | 2020 | 1023 | 0.030 |
Why?
|
| Larynx | 1 | 2014 | 56 | 0.030 |
Why?
|
| Poly I-C | 1 | 2013 | 58 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 37 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 357 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2018 | 1003 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 344 | 0.020 |
Why?
|
| Atrial Function | 1 | 2013 | 10 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 194 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 396 | 0.020 |
Why?
|
| Comorbidity | 1 | 2018 | 1662 | 0.020 |
Why?
|
| Trimethoprim | 1 | 2012 | 7 | 0.020 |
Why?
|
| Sulfadoxine | 1 | 2012 | 4 | 0.020 |
Why?
|
| Sulfamethoxazole | 1 | 2012 | 7 | 0.020 |
Why?
|
| Peyer's Patches | 1 | 2012 | 7 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 2028 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2012 | 43 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 2012 | 321 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2012 | 105 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 288 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2013 | 179 | 0.020 |
Why?
|
| Plethysmography | 1 | 2012 | 104 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2012 | 37 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 112 | 0.020 |
Why?
|
| Lubiprostone | 1 | 2012 | 9 | 0.020 |
Why?
|
| Perinatal Care | 1 | 2013 | 59 | 0.020 |
Why?
|
| Overweight | 1 | 2017 | 614 | 0.020 |
Why?
|
| Alprostadil | 1 | 2012 | 29 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 501 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2012 | 21 | 0.020 |
Why?
|
| Genes, Bacterial | 1 | 2012 | 152 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2013 | 152 | 0.020 |
Why?
|
| Electrolytes | 1 | 2012 | 54 | 0.020 |
Why?
|
| Leukocytes | 1 | 2013 | 296 | 0.020 |
Why?
|
| Chlorine | 1 | 2012 | 59 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 410 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 1898 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2012 | 48 | 0.020 |
Why?
|
| Genotyping Techniques | 1 | 2012 | 71 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2012 | 123 | 0.020 |
Why?
|
| Tricuspid Valve | 1 | 2012 | 43 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 2383 | 0.020 |
Why?
|
| Proteolysis | 1 | 2012 | 172 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2012 | 63 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 1399 | 0.020 |
Why?
|
| Marijuana Smoking | 1 | 2015 | 249 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2012 | 273 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2012 | 157 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2021 | 2344 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 338 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2012 | 311 | 0.020 |
Why?
|
| Bacteria, Anaerobic | 1 | 2010 | 25 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 421 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 770 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2014 | 784 | 0.020 |
Why?
|
| Diet | 1 | 2018 | 1278 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 552 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 2010 | 31 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 527 | 0.020 |
Why?
|
| Neurons | 1 | 2019 | 1652 | 0.020 |
Why?
|
| Endoscopy | 1 | 2012 | 317 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 283 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 507 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2018 | 1244 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2009 | 35 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 2009 | 48 | 0.020 |
Why?
|
| Biodiversity | 1 | 2012 | 311 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2009 | 48 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2012 | 655 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 2009 | 67 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 49 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 1115 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2012 | 544 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 2009 | 80 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 968 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 2009 | 96 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 534 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 426 | 0.020 |
Why?
|
| Water | 1 | 2012 | 448 | 0.020 |
Why?
|
| Anxiety | 1 | 2016 | 1122 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2009 | 72 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 669 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1276 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 780 | 0.020 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 428 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 255 | 0.020 |
Why?
|
| Chemokines | 1 | 2009 | 217 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2008 | 41 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 181 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2008 | 85 | 0.020 |
Why?
|
| Nonverbal Communication | 1 | 2007 | 6 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 507 | 0.020 |
Why?
|
| Pedigree | 1 | 2009 | 515 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 217 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 843 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 351 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2012 | 835 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2007 | 232 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 1559 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 474 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 287 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 342 | 0.010 |
Why?
|
| Monocytes | 1 | 2009 | 539 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 782 | 0.010 |
Why?
|
| Reaction Time | 1 | 2007 | 434 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2009 | 501 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2012 | 1782 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3916 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2008 | 779 | 0.010 |
Why?
|
| Hospitals | 1 | 2008 | 733 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1430 | 0.010 |
Why?
|